Maxim Group set a $10.00 price objective on Cytosorbents Corp (NASDAQ:CTSO) in a research report report published on Monday morning. The brokerage currently has a buy rating on the medical research company’s stock.
A number of other equities research analysts also recently weighed in on CTSO. B. Riley restated a buy rating and set a $11.25 price target on shares of Cytosorbents Corp in a research report on Wednesday, March 1st. HC Wainwright raised their price target on Cytosorbents Corp from $11.50 to $13.00 and gave the company a buy rating in a research report on Monday, March 6th. Finally, Aegis restated a buy rating on shares of Cytosorbents Corp in a research report on Tuesday, March 7th. Five investment analysts have rated the stock with a buy rating, Cytosorbents Corp presently has an average rating of Buy and an average target price of $13.45.
Cytosorbents Corp (NASDAQ:CTSO) opened at 4.35 on Monday. The firm has a 50-day moving average price of $4.61 and a 200-day moving average price of $5.23. Cytosorbents Corp has a one year low of $3.95 and a one year high of $6.90. The firm’s market cap is $122.27 million.
Cytosorbents Corp (NASDAQ:CTSO) last released its quarterly earnings results on Monday, May 8th. The medical research company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.06. Cytosorbents Corp had a negative return on equity of 193.13% and a negative net margin of 120.04%. The business had revenue of $3.11 million for the quarter, compared to the consensus estimate of $2.99 million. On average, equities analysts expect that Cytosorbents Corp will post ($0.28) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Skylands Capital LLC increased its stake in Cytosorbents Corp by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock worth $1,425,000 after buying an additional 293,600 shares during the last quarter. Segantii Capital Management Ltd increased its stake in Cytosorbents Corp by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock worth $122,000 after buying an additional 23,100 shares during the last quarter. Cowen Group Inc. purchased a new stake in Cytosorbents Corp during the first quarter worth $248,000. Vanguard Group Inc. increased its stake in Cytosorbents Corp by 3.9% in the first quarter. Vanguard Group Inc. now owns 567,116 shares of the medical research company’s stock worth $2,552,000 after buying an additional 21,312 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Cytosorbents Corp by 0.5% in the first quarter. Geode Capital Management LLC now owns 126,883 shares of the medical research company’s stock worth $570,000 after buying an additional 606 shares during the last quarter. Institutional investors and hedge funds own 6.07% of the company’s stock.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.